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Abstract: DUSP6 is a dual-specificity phosphatase (DUSP) involved in breast cancer progression,
recurrence, and metastasis. DUSP6 is predominantly cytoplasmic in HER2+ primary breast cancer
cells, but the expression and subcellular localization of DUSPs, especially DUSP6, in HER2-positive
circulating tumor cells (CTCs) is unknown. Here we used the DEPArray system to identify and
isolate CTCs from metastatic triple negative breast cancer (TNBC) patients and performed single-cell
NanoString analysis to quantify cancer pathway gene expression in HER2-positive and HER2-negative
CTC populations. All TNBC patients contained HER2-positive CTCs. HER2-positive CTCs were
associated with increased ERK1/ERK2 expression, which are direct DUSP6 targets. DUSP6 protein
expression was predominantly nuclear in breast CTCs and the brain metastases but not pleura or
lung metastases of TNBC patients. Therefore, nuclear DUSP6 may play a role in the association with
cancer spreading in TNBC patients, including brain metastasis.
Keywords: circulating tumor cells (CTCs); DEPArray; dual-specificity phosphatase; HER2;
brain metastasis; single cell analysis; triple-negative breast cancer (TNBC)
1. Introduction
Breast cancer is the most common malignant disease in women worldwide. While there has
been significant progress in breast cancer treatment over recent decades through new chemotherapies,
hormone therapies, targeted therapies, and more recently immunotherapies, 25–40% of breast cancer
patients still develop primary resistance and metastasis to eventually die from their disease [1,2].
Identification of predictive resistance biomarkers has so far remained elusive, especially in triple
negative breast cancer (TNBC), a breast cancer molecular subtype with currently few treatment options
and an often-aggressive disease course.
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Epithelial to mesenchymal transition (EMT) is a biological program in which epithelial cells
lose cell–cell junctions, apical–basal polarity, and acquire an invasive mesenchymal phenotype.
EMT is induced via several interacting signaling pathways including the WNT, TGF-β, Notch,
Hedgehog, PI3-kinase/AKT, PKC-theta, and mitogen-activated protein kinase (MAPK) pathways [3–5].
EMT is implicated in cancer initiation, progression, metastasis, resistance to conventional therapies,
and recurrence by inducing cancer stem cells (CSCs), tumor-initiating cells (TICs), and circulating
tumor cells (CTCs) [3,5,6].
Breast CTCs are defined as cells circulating in the blood that lack CD45 expression but express
cytokeratins 7, 8, 18, and 19 [7,8]. Breast CTCs are associated with progressive cancer and a higher risk
of recurrence and metastasis [6,9]. Both HER2-positive CTCs and HER2-negative CTCs have been
detected in patients with HER2-negative primary tumors (e.g., TNBCs) after adjuvant chemotherapy
for the management of their primary breast cancer [9–12]. HER2-positive CTCs are associated with
progression following multiple courses of systemic therapy in HER2-negative metastatic breast cancer
patients [13].
Dual-specificity phosphatases (DUSPs) are a family of proteins responsible for dephosphorylating
threonine/serine and tyrosine residues on their substrates, mainly MAP kinases. Several DUSPs are
implicated in breast cancer metastasis, for example, DUSP1, DUSP4, and DUSP6 [4,14]. DUSP1 and
DUSP4 are predominantly expressed in the nucleus, while DUSP6 is predominantly cytoplasmic [4].
DUSP6 has an interdomain linker region that contains a binding motif of ERK1/2 and nuclear export
signal (NES) [15]. NES mediated nuclear-cytoplasmic shuttling of DUSP6 undergoes a highly specific
interaction with ERK1 and ERK2 at dual threonine and tyrosine residues of the Thr-Glu-Tyr (TEY)
motif, thereby inactivating DUSP6 [16]. Caspase-3 cleavage of DUSP6 mediates the subcellular
localization and activation of ERK1/2 [15]. DUSP6 phosphorylation and ERK1/2 dephosphorylation
creates a negative feedback loop to control ERK activity and indirectly the MAPK signal, which is
vital for cellular proliferation and differentiation [15–22]. DUSP6 is enriched in HER2-positive breast
cancer tumor [23], the overexpression of which confers resistance to tamoxifen endocrine therapy [4,24],
and we previously showed that DUSP6 knockdown by RNA interference increased CSC formation
but inhibited cell proliferation in TNBC cell lines in vitro [4,21]. DUSP6 is also upregulated in the
cytoplasm of primary malignant breast cancer cells in HER2-positive breast cancer patients regardless
of estrogen receptor/progesterone receptor (ER/PR) status [4]. Importantly, DUSP6 is cytoplasmic in
ER−PR−HER2+ tissue but not in TNBCs [4]. The nuclear role of DUSP6 in EMT and metastasis in
TNBC remains elusive.
HER2-positive CTCs were recently identified in breast cancer patients with HER2-negative primary
tumors [8]. However, it is unknown how the mRNA profiles of HER2-positive CTCs and HER2-negative
CTCs differ. We therefore analyzed mRNA profiles in HER2-positive CTCs and HER2-negative CTCs
isolated from five metastatic breast cancer patients with TNBC. At least one HER2-positive CTC was
detected in every patient. mRNA expression profiles were distinct in HER2-positive and HER2-negative
CTCs in the same patient. Pathway analysis revealed differential expression of genes involved in
ERK1/2-MAPK signaling between HER2-positive and HER2-negative CTCs and involvement of DUSP6.
We report for the first time that nuclear DUSP6 was present in CTCs from metastatic breast cancer
patients regardless of CTC HER2 status. Importantly, nuclear-biased DUSP6 was also present in
brain metastases but not pleura or lung metastases in TNBC patients, suggesting that the nuclear
DUSP6-associated pathway participates in cancer spreading in TNBC, including brain metastasis.
2. Results
2.1. HER2-Positive and HER2-Negative CTCs Detected and Isolated from Primary TNBC Patients
CD45−/pan-CK+ CTCs along with HER2-positive and HER2-negative CTC sub-populations were
identified, enumerated and isolated from five metastatic TNBC patients using the DEPArray system
(Silicon Biosystems, Castel Maggiore, Italy). There were 5 to 150 CTCs per 7.5 mL blood (in average of
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103 CTCs per 7.5 mL blood) (Figure 1A,B). All TNBC patients in this group had HER2-positive CTCs
detected ranging from 10% to 100% of total (Figure 1B–D). Post standard chemotherapy in combination
with an inhibitor targeting Lysine-specific histone demethylase 1 (LSD1), HER2-positive CTCs were
more frequent in patients with disease progression with increased total CTC number and less frequent
in patients with stable disease (Figure 1D).Int. J. Mol. Sci. 2019, 20, x 4 of 14 
 
 
Figure 1. HER2-positive and negative circulating tumor cells (CTCs) have distinct mRNA profiles in 
metastatic triple negative breast cancer (TNBC) patients. CD45-negative enriched PBMCs were 
labelled with anti-human CD45-APC and pan-cytokeratin-FITC for DEPArray CTC enumeration and 
isolation. (A) CTCs were detected in metastatic TNBC patients. CTCs were enumerated in five 
metastatic TNBC patients using the DEPArray platform. Data represent the mean of CTC counts ± 
standard deviation in 7.5 mL equivalent whole blood. (B) Identification and isolation of HER2-
positive and negative CTCs in the same patients. Plot shows the gating strategy for identifying HER2-
Figure 1. HER2-positive and negative circulating tu r cells (CTCs) have distinct mRNA profiles in
metastatic triple negative bre st cancer (TNBC) patients. CD45-negative enriched P s ere labelled
with anti-human CD45-APC and pan-cytokeratin-FITC for DEPArray CTC enumeration and isolation.
(A) CTCs were detected in metastatic TNBC patients. CTCs were enumerated in five metastatic TNBC
patients using the DEPArray platform. Data represent the mean of CTC counts ± standard deviation in
7.5 mL equivalent whole blood. (B) Identific on and is lation of HER2-positive and egative CTCs in
the same patients.
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Plot shows the gating strategy for identifying HER2-positive and negative CTCs using DEPArray.
Example images are indicated with scale bars (10 µm). (C) HER2-positive CTCs and HER2-negative
CTCs using DEPArray. BF: brightfield. (D) CTC HER2 proportions over the course of chemotherapy in
combination of Lysine-specific histone demethylase 1 (LSD1) inhibitor. Plot represents the number
of HER2-positive and negative CTCs from 7.5 mL equivalent whole blood. (E) HER2-positive CTCs
show distinct mRNA profiles in genes involved in mitogen-activated protein kinase (MAPK) signaling.
NanoString analysis was performed using their pan-cancer progression panel to investigate differential
gene expression in HER2-positive and negative CTCs isolated from the same patient. Data generated by
pathway analysis using nSolver 4.0 software (NanoString). Orange indicates higher mRNA expression
and blue indicates lower expression.
2.2. Distinct ERK1/2-MAPK Pathway Gene Profiles in HER2-Positive CTCs and HER2-Negative CTCs
To assess the mRNA profiles of HER2-positive and negative CTCs, both populations were
harvested from the same patient using the DEPArray system and, after cDNA synthesis and un-biased
pre-amplification, expression of 739 mRNAs from the NanoString PanCancer Progression panel
assessed. ERK1/ERK2-MAPK signaling pathway analysis showed that HER2-positive CTCs had
decreased AKT1/2 mRNA expression and increased MAPK1 and MAPK3 expression, which are the
direct substrates of DUSP6 (Figure 1E).
2.3. Nuclear Distribution of DUSP6 in CTCs and Brain Metastases from TNBC Patients
Since DUSP6 directly dephosphorylates ERK1/ERK2, we reasoned that DUSP6 may participate in
HER2-positive CTCs in metastatic breast cancer patients. DUSP6 showed nuclear and cytoplasmic
expression and was biased towards nuclear expression in the CTCs as measured by the ratio of nuclear
to cytoplasmic (Fn/c), (Figure 2A,B and Figure S1C). Moreover, nuclear DUSP6 was also co-expressed
with cell surface vimentin (CSV) and ABCB5 known mesenchymal markers in CTCs (Figure 2A–C).
We also examined the distribution of DUSP6 protein expression in brain metastasis tissue in TNBC
patients (Figure 2C,D and Figure S1A,B). In 19 out of 21 patients, approximately 40% of cells were
triple-positive for DUSP6, CSV, and ABCB5 (Figure 2C). Surprisingly, DUSP6 nuclear expression was
also observed in the brain tissue, with highest DUSP6 expression observed in CSV+ABCB5+DUSP6+
triple-positive cells, (Figure 2C). To further understand whether nuclear expression of DUSP6 is
exclusively presented in brain metastasis, we examined five lung and pleura metastases tissues from
TNBC patients. Interestingly, virtually no neoplastic cell had nuclear DUSP6 expression in all five
samples, although large numbers of CSV+ABCB5+ cells were detected (Figure 2E,F).
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vehicle, Abraxane (nab-paclitaxel, 30 mg/kg), or anti-PD1 (RMP1–14, 10 mg/kg) using the ASI digital 
pathology system. We first examined the changes in tumor volume caused by treatment with either 
Abraxane or anti-PD1 immunotherapy (Figure 3A) reduced overall tumor volume equally (Figure 
3A). In surviving 4T1 tumor cells in Abraxane or anti-PD1-treated mice, nuclear DUSP6 was enriched 
in both triple-positive cells (CSV+ABCB5+DUSP6+) and the double-positive ABCB5+DUSP6+ tumor cell 
pool (Figure 3B). We next examined the Fn/c of DUSP6 expression that revealed that DUSP6 is 
Figure 2. Nuclear-biased dual-specificity phosphatase 6 (DUSP6) in CTCs and brain metastases from
metastatic TNBC patients. (A) Nuclear DUSP6 presented in CTCs from metastatic breast cancer patients.
CTCs were labelled wit anti-human DUSP6, cell surface vimentin (CSV), ABCB5, and DAPI for
microscopy. (B) The n clear bias of DUSP6 in CTCs fro stage IV metastatic breast cancer patients
(n = 5 patients). Nuclear/cytoplasmic intensity of DUSP6 was measured by microscopy. (C) DUSP6
expression in breast cancer metastases to the brain. Fluorescence labelling of DUSP6, CSV, and ABCB5
was performed for ASI micr scopy analysis. Bar graph represent cells double-positive for either
DUSP6/ABCB5/CSV or triple-positive for all three markers. The second bar graph displays the nuclear
fluorescence intensity in double- or triple-positive cells for DUSP6. >500 cells counted per patient.
Representat v image f nucl ar DUSP6 xpression i (D) brain metastasis tissu (n = 21 patients).
(E) DUSP6 expression in breast cancer metastases to the lung and (F) pleura (n = 5 patients) from
metastatic TNBC patients. Bar graph represents cells double-positive for either DUSP6/ABCB5/CSV or
triple-positive for ll hree markers. Scale bars = 10 µm and are shown in orange. Data represent mean
± SE. Unpaire t-test. *p < 0.05, ****p < 0.0001 denote significant differences.
2.4. Nuclear Distribution of DUSP6 in Primary Tumor Sections in the Chemotherapy or Immunotherapy
Treated 4T1 Metastatic Mouse Model
To under tand whether nuclear DUSP6 is associ with drug resist nce, we next examined
DUSP6 expression in the 4T1 TNBC metastatic mouse breast cancer model treated with control
vehicle, Abraxane (nab-paclitaxel, 30 mg/kg), or anti-PD1 (RMP1–14, 10 mg/kg) using the ASI digital
pathology system. We first examined the changes in tumor volume caused by treatment with either
Abraxane or anti-PD1 immunotherapy (Figure 3A) reduced overall tumor volume equally (Figure 3A).
In surviving 4T1 tumor cells in Abraxane or anti-PD1-treated mice, nuclear DUSP6 was enriched in
both triple-positive cells (CSV+ABCB5+DUSP6+) and the double-positive ABCB5+DUSP6+ tumor
cell pool (Figure 3B). We next examined the Fn/c of DUSP6 expression that revealed that DUSP6 is
predominantly cytoplasmic in control tumors but becomes nuclear biased in surviving tumor cells
following treatment with Abraxane or anti-PD1 (Figure 3C). DUSP6 expression correlated with tumor
cell survival in response to either chemotherapy (Abraxane) or immunotherapy (anti-PD1) (Figure S2).
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2.5. Novel Inhibition of Nuclear DUSP6 Mediated the Expression of ABCB5 and CSV in vitro 
To understand the effect of inhibition of nuclear DUSP6 in TNBC, we designed a novel 
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Figure 3. Nuclear-biased DUSP6 in the 4T1 metastatic mouse cancer model. (A) Treatment regimen
using the BALB/c 4T1 breast cancer model and day 15 tumor volumes of mice treated with vehicle control,
Abraxane, or PD-1 (n = 4). (B) DUSP6 expression in the primary 4T1 tumor model. Fluorescence labelling
of DUSP6, CSV, and ABCB5 was performed for ASI microscopy analysis. Bar graph represents cells
double-positive for either DUSP6/ABCB5/CSV or triple-positive for these three markers. n = 3 mice
per group (>500 cells per patient counted). Data represent mean ± SE. Unpaired t-test. ****p < 0.0001
denote significant differences. Example images of each group are indicated with scale bars (10 µm).
(C) DUSP6 Fn/c (ratio of nuclear to cytoplasmic staining) was quantified in the primary 4T1 tumor
model. Fn/c was determined by performing ASI microcopy analysis and using ImageJ-Fiji to determine
the ratio. Bar graphs represent fn/c mean ± SE. Unpaired t-test., ****p < 0.0001 denote significant
differences. Example images are in 3B.
2.5. Novel Inhibition of Nuclear DUSP6 Mediated the Expression of ABCB5 and CSV In Vitro
To understand the effect of inhibition of nuclear DUSP6 in TNBC, we designed a novel competitive
peptide inhibitor targeting a bipartite nuclear localization signal (NLS) of DUSP6 that was identified
using the NLS Mapper predictive tool. In MDA-MB-231 TNBC cells, treatment of Paclitaxel induced
nuclear translocation of DUSP6. In comparison, the DUSP6 NLS peptide inhibitor significantly reduced
nuclear DUSP6 expression (Figure 4A) and inhibited the expression of CSV and ABCB5 in vitro
suggesting alteration of protein function (Figure 4A,B). These results suggest that inhibition of nuclear
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expression of DUSP6 subsequently impacts expression of the mesenchymal, stem-like markers such as
CSV or ABCB5.
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Figure 4. Inhibition of nuclear DUSP6 with novel peptide inhibitor. DUSP6, CSV and ABCB5 were
labelled in TNBC cell line, DA-MB-231 and treated with either vehicle alone, Paclitaxel (PTX) or
DUSP6 Nuclear Peptide inhibitor ( SP6 PEP, C1 = 60 mg/ L) or a co bination (PTX + C2 40 mg/mL)
with n > 20 individual cells. Representative i ages for each dataset are shown (A). Graphs represent the
Fn/c, nuclear fluorescence intensity (NFI), cytoplasmic fluorescence intensity (CFI) or total fluorescence
intensity (TFI) measured with the ASI automated digital pathology system (B). Scale bar is in orange
and equals 10 µM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 denote significant differences. ns
denotes non-significant.
2.6. Nuclear Association of DUSP6 with P300 and H3K9me2
Nucleosomes are enriched in highly compacted chromatin structures which are transcriptionally
silent. An important mechanism of regulating gene expression is chromatin remodeling which can be
orchestrated via a number of mechanisms including post-translational modifications (PTMs) of histone
proteins such as the repressive mark histone H3K9me2 as well co-activator proteins such as the histone
acetyltransferase P300 that mediate active gene transcription and we have previously show to interact
with DUSP family members [4].
Our results of H3k9me2 and DUSP6 co-expression revealed that while there was some positive
co-localization the score was low (Figure 5). Whereas analysis revealed that P300 positively co-localized
with DUSP6 in the nucleus of these CTCs with a stronger positive score (Figure 5). Collectively our
data suggest that DUSP6 associates with P300 akin to our previous results for DUSP4 [4]. This suggests
a potential role for DUSP6 to mediate active gene transcription programs in CTCs from metastatic
breast cancer patients.
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Figure 5. Nuclear DUSP6 interaction with P300 or H3k9me2. Confocal laser scanning microscopy
was performed on CTCs (circulating tumor cells) isolated from metastatic breast cancer patients
(Stage IV n = 10). Cells were fixed and probed with primary rabbit antibodies to DUSP6 and primary
mouse antibodies to P300 or H3k9me2 followed by the corresponding secondary antibody conjugated
to Alexa-Fluor 568 or Alexa-Fluor 488. Representative images for each antibody dataset pair are
shown: red = p300 or H3k9me2; green = DUSP6. (A) The The Pearson correlation coefficient (PCC)
was determined as described in methods. PCC indicates the strength of relation between the two
fluorochrome signals for at least 20 individual cells ± SE. Bar graphs (B) indicate the total NFI of DUSP6,
p300, or H3K9me2 as measured using ASI software to select the nucleus of each cell and measure the
total NFI signal minus background for at least 20 individual cells ± SE. Scale bar is in orange and equals
10 µM.
3. Discussion
TNBC remains the most difficult group of metastatic breast cancers to manage due to a lack
of targetable proteins expressed in these tumor cells [1]. Despite therapeutic advances, the overall
response and survival rates for patients with TNBC are low using conventional chemotherapy and novel
immunotherapy compared to other solid organ malignancies. Increased CTC numbers are associated
with rapid cancer progression and a higher risk of recurrence and metastasis. Here we confirmed the
presence of both HER2-positive and negative CTCs in patients with a primary tissue diagnosis of TNBC,
supporting previous findings [9,11,12]. For the first time, we compared the mRNA profiles of these two
populations directly in the same patient using a panel of cancer progression-related genes, and found
differential MAPK pathway gene expression. Specifically, there was increased expression of MAPK1/2,
encoding ERK1/2, which are the direct dephosphorylation targets of DUSP6, in HER2-positive CTCs.
DUSP6 is predominately expressed in the cytoplasm of breast cancer cells such as the commonly
used cell lines MCF-7 and MDA-MB-231 [4]. DUSP6 nuclear expression increases in tumor cells
that have transformed into CSCs via EMT [4]. Dual inhibition of DUSP6 and DUSP1 significantly
reduces CSC formation in vitro. We previously showed that DUSP6 was exclusively cytoplasmic in
primary HER2+ER−PR− breast cancers from metastatic breast cancer patients, with no nuclear DUSP6
expression in primary TNBCs [4]. Interestingly, in CTCs, DUSP6 was nuclear in all vimentin-positive
mesenchymal CTCs from stage IV metastatic patients evaluated. In 19 out of 21 patients TNBC
metastatic breast cancer patient brain metastases, DUSP6 had nuclear expression, suggesting that
the brain metastasis may form from CTCs via a nuclear DUSP6-dependent pathway. In comparison,
our previous study showed that TNBC patients had undetectable levels of nuclear DUSP6 expression [4].
Overall, this suggests that distinct mechanisms are likely at play in the aggressive cancer cells in
primary tissue, lung and pleura metastases tissue compared to brain metastases events. Future studies,
particularly larger blind studies, will be required to fully validate the results of this study.
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These results have a number of potential important implications for patient care. First, a subset of
TNBC patients may in fact benefit from trastuzumab (Herceptin) therapy if they harbor significant
numbers of HER2-positive CTCs and that HER2-CTC testing may be required in routine practice.
Second, the presence of HER2-positive CTCs in primary TNBC may be a risk factor for metastatic
disease, especially to the brain. Third, the nuclear distribution of DUSP6 in CTCs and brain metastases
may be prognostic, the majority of metastatic breast cancer patients with brain metastases had cancer
cells positive for DUSP6 and all CTCs examined were also DUSP6 positive. Four, the novel nuclear
DUSP6 peptide inhibitor can potentially reduce the risk of brain metastasis. Therefore, DUSP6 may
be a therapeutic target to prevent or treat brain metastasis. We also examined DUSP6 expression in
surviving tumor cells in a mouse model of breast cancer metastasis treated with Abraxane or anti-PD1.
DUSP6-positive cells were enriched in surviving tumor cells, which may indicate a role in resistance to
chemotherapy or immunotherapy.
Although nuclear DUSP6 expression was present in CTCs and in the brain metastases of 19 out of
21 patients TNBC patients, this result requires further confirmation in a larger cohort and the samples
need to be stratified based on the original hormonal status of the primary tumor in future experiments.
Nuclear DUSP6 was not expressed in pleura or lung metastases tissue of TNBC patients, and it remains
uncertain whether nuclear-biased DUSP6 in CTCs is exclusively associated with brain metastasis.
DUSP6 expression should be analyzed in metastases at other sites as well as obtaining matched CTCs
and metastatic lesion tissue samples from different sites to compare for DUSP6 expression. In addition,
future studies should examine the nuclear interaction partners of DUSP6 along with the epigenetic
machinery that DUSP6 may regulate in cancer biology as well as the underpinning gene signatures
associated with DUSP6 in brain metastases. Also, further work should investigate if MAPKs such as
ERK1/2 and AKT1/2 are directly mediated by nDUSP6 enriched HER2-postive CTCs. Overall these
findings suggest the potential importance of developing nuclear targeting DUSP6 therapeutics for
targeting aggressive TNBC cancer spreading, including brain metastasis.
4. Materials and Methods
4.1. Patients
Peripheral blood (25 to 40 mL) was collected into 3 or 4 EDTA tubes from five patients with
radiologically and histologically confirmed metastatic TNBC before starting a new chemotherapy
regimen. Samples were maintained at room temperature and processed within four hours after blood
collection. Samples were anonymized, and operators were blinded to clinical outcome.
4.2. Tissues
Tissue from routinely processed archival primary and metastatic breast cancers from the
five patients were retrieved from the Department of Anatomical Pathology, ACT Pathology,
Canberra Hospital. The tissue diagnosis and receptor status were reviewed by a specialized breast
pathologist (JED), who excluded areas of tumor necrosis.
4.3. Animal Studies
Five-week-old female BALB/c mice were obtained from the Animal Resources Centre (ARC), Perth,
and allowed to acclimatize for one week in the containment suites at The John Curtin School of Medical
Research (JCSMR). All experimental procedures were performed in accordance with the guidelines and
regulations approved by the Australian National University Animal Experimentation Ethics Committee
(ANU AEEC). Mice were shaved at the site of inoculation the day before subcutaneous injection with
2 × 105 4T1 cells in 50 µL PBS into the right mammary gland. Treatment was started on day 12 post
inoculation, when tumors reached approximately 50 mm3. Tumors were measured using external
calipers and volume calculated using a modified ellipsoidal formula 12 (a/b
2), where a = longest diameter
and b = shortest diameter. Mice were treated with the chemotherapy Abraxane (30 mg/kg) and anti-PD1
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immunotherapy (10 mg/kg) every 5 days (twice). All treatments were given intraperitoneally in PBS.
Tumors were collected on day 27 post inoculation of 4T1 cells for immunofluorescence microscopy.
4.4. Ethics
All subjects gave their informed consent for inclusion before study participation. The study was
conducted in accordance with the Declaration of Helsinki, and the ACT Heath Human Research Ethics
Committee (ID code: ETH.11.15.217) approved the protocol on the 4 December 2017.
4.5. CTC Enrichment
CD45-positive cell depletion was performed to enrich CD45-negative expressing cells using
the RosettSep CD45 depletion kit (StemCell Technologies, Vancouver, Canada) according to the
manufacturer’s instructions and as described previously [5].
4.6. CTC Detection, Imaging, and Isolation
CD45-negative enriched cells were stained with antibodies targeting human CD45, pan-cytokeratin,
and HER2/vimentin/DUSP6 prior to CTC enumeration and sorting by DEPArray V2 or NXT
(Silicon Biosystems, Italy). CTCs were defined as nucleated cells lacking CD45 and expressing
pan-cytokeratin (CK7, CK8, CK18, and CK19) as described previously [5]. CTCs for mRNA analysis
were lysed using the Single Cell Lysis Kit (Thermo Fisher Scientific, Waltham, MA, USA) and stored at
–80 ◦C prior to further analysis. CTCs for immunofluorescence microscopy analysis were cytospun
onto coverslips and fixed prior to fluorescence labeling and imaging.
4.7. RNA Isolation, cDNA Synthesis and Pre-Amplification from CTCs
Lysed single CTCs were treated with DNAse I (Thermo Fisher Scientific), and the RNA was
converted to cDNA using Superscript VILO (Thermo Fisher Scientific). Pre-amplification was performed
using the Nanostring Pre-Amp kit (NanoString Technologies, Seattle, WA).
4.8. Nanostring Analysis
The nCounter XT protocol was used for hybridization, and the data were captured using
a Nanostring Sprint instrument (NanoString Technologies). Data analysis was performed using nSolver
4.0 (NanoString Technologies).
4.9. ASI Microscopy
For high-throughput microscopy in human tissue samples, protein targets were localized by
confocal laser scanning microscopy. Single 0.5 µm sections were obtained using an Olympus-ASI
automated microscope with a 60× oil immersion lens running ASI software. The final image was
obtained by employing a high-throughput automated stage with ASI spectral capture software. Digital
images were analyzed using automated ASI software (Applied Spectral Imaging, Carlsbad, CA) to
determine the distribution and intensities automatically with automatic thresholding and background
correction of the average nuclear fluorescence intensity (NFI), allowing for the specific targeting of
nuclear expression of proteins of interest (in this case DUSP6).
4.10. Nuclear to Cytoplasmic Fluorescence Ratio (Fn/c) Analysis
Digital confocal images were analyzed using Fiji-ImageJ software (Schindelin et al., 2012) to
determine the TNFI, TCFI, TFI, or the nuclear to cytoplasmic fluorescence ratio (Fn/c) using the
equation: Fn/c = (Fn − Fb)/(Fc − Fb), where Fn is nuclear fluorescence, Fc is cytoplasmic fluorescence,
and Fb is background fluorescence. A minimum of n = 20 cells were analyzed for each sample set.
The Mann–Whitney non-parametric test (GraphPad Prism, GraphPad Software, San Diego, CA) was
used to determine significant differences between datasets.
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4.11. Statistical Analysis
PRISM-Graph pad was used to calculate the significant differences using the Mann–Whitney
Unpaired t-test. Significance was plotted as indicated: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001
5. Conclusions
We showed for the first time that nuclear-biased DUSP6 was present in CTCs from TNBC patients.
Importantly, nuclear DUSP6 was also observed in brain metastases but not lung or pleura metastases
from metastatic TNBC patients, while DUSP6 was always cytoplasmic in the primary tumor tissue.
These results indicate that a nuclear-biased DUSP6-dependent pathway may be involved in cancer
spreading in TNBC patients, including brain metastasis. Inhibition of DUSP6 nuclear translocation
reduced the expression of aggressive mesenchymal protein and may be a good candidate therapeutic
target to reduce or prevent metastases via CTC in metastatic breast cancer and TNBC patients.
Future studies are required to address the precise transcriptional programs underpinning nuclear
DUSP6 in cancer spreading in TNBC, especially in brain metastases.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/12/3080/s1.
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